Hitt M - Search Results

1

Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma--a phase 1 study.

Trudel S, Li Z, Dodgson C, Nanji S, Wan Y, Voralia M, Hitt M, Gauldie J, Graham FL, Stewart AK. Trudel S, et al. Among authors: hitt m. Leukemia. 2001 May;15(5):846-54. doi: 10.1038/sj.leu.2402077. Leukemia. 2001. PMID: 11368448 Clinical Trial.

2

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.

Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y, Gauldie J, Graham FL, Dancey J, Stewart AK. Trudel S, et al. Among authors: hitt m. Cancer Gene Ther. 2003 Oct;10(10):755-63. doi: 10.1038/sj.cgt.7700626. Cancer Gene Ther. 2003. PMID: 14502228 Clinical Trial.

3

Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.

Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS, Hawley RG, Stewart AK. Wen XY, et al. Among authors: hitt m. Cancer Gene Ther. 2001 May;8(5):361-70. doi: 10.1038/sj.cgt.7700321. Cancer Gene Ther. 2001. PMID: 11477456

4

Human adenovirus vectors for gene transfer into mammalian cells.

Hitt MM, Addison CL, Graham FL. Hitt MM, et al. Adv Pharmacol. 1997;40:137-206. doi: 10.1016/s1054-3589(08)60140-4. Adv Pharmacol. 1997. PMID: 9217926 Review. No abstract available.

5

Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors.

Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL. Addison CL, et al. Among authors: hitt mm. Gene Ther. 1998 Oct;5(10):1400-9. doi: 10.1038/sj.gt.3300731. Gene Ther. 1998. PMID: 9930346

6

Gene vectors for cytokine expression in vivo.

Hitt MM, Gauldie J. Hitt MM, et al. Curr Pharm Des. 2000 Apr;6(6):613-32. doi: 10.2174/1381612003400551. Curr Pharm Des. 2000. PMID: 10788600 Review.

7

Adenovirus vectors for human gene therapy.

Hitt MM, Graham FL. Hitt MM, et al. Adv Virus Res. 2000;55:479-505. doi: 10.1016/s0065-3527(00)55014-3. Adv Virus Res. 2000. PMID: 11050953 Review. No abstract available.

8

Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12.

Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL. Bramson J, et al. Among authors: hitt m. Hum Gene Ther. 1996 Feb 10;7(3):333-42. doi: 10.1089/hum.1996.7.3-333. Hum Gene Ther. 1996. PMID: 8835220

9

Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12.

Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL. Bramson JL, et al. Among authors: hitt m. Hum Gene Ther. 1996 Oct 20;7(16):1995-2002. doi: 10.1089/hum.1996.7.16-1995. Hum Gene Ther. 1996. PMID: 8930660

10

Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination.

Bramson JL, Hitt M, Gauldie J, Graham FL. Bramson JL, et al. Among authors: hitt m. Gene Ther. 1997 Oct;4(10):1069-76. doi: 10.1038/sj.gt.3300508. Gene Ther. 1997. PMID: 9415313

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters